[Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].

Nihon Ganka Gakkai zasshi

Volumn 115, Issue 9, 2011, Pages 825-831

  Yanagi, Yasuo ^a   Aihara, Yukiko ^b   Fukuda, Takashi ^b   Hashimoto, Hideki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A;

AGED; ARTICLE; ASIAN; CASE REPORT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; HUMAN; MALE; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; ASIAN CONTINENTAL ANCESTRY GROUP; CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856399894     PISSN: 00290203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)